[Treatment of advanced non-small-cell lung cancer with driver mutations]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Advanced non-small-cell lung cancer (NSCLC) is increasingly recognized as a heterogeneous disease.
• Molecular biomarkers, including driver mutations, are crucial for classifying NSCLC subtypes.
• Identifying targetable molecular alterations has revolutionized treatment approaches.

Purpose of the Study:

• To review the diagnostic and therapeutic landscape for advanced NSCLC in Germany and Europe.
• To discuss the impact of identifying driver mutations on treatment strategies.
• To highlight the benefits of targeted therapies over traditional chemotherapy.

Main Methods:

• Literature review of studies on NSCLC molecular biomarkers and targeted therapies.
• Analysis of treatment outcomes for patients with EGFR mutations, ALK translocations, and ROS1 rearrangements.
• Discussion of the current status of diagnostics and therapeutics in Germany and Europe.

Main Results:

• Targetable molecular alterations (e.g., EGFR mutations, ALK translocations, ROS1 rearrangements) are identified in a subset of NSCLC patients.
• Tyrosine kinase inhibitors (TKIs) targeting these alterations demonstrate superior response rates, progression-free survival, and quality of life compared to chemotherapy.
• Personalized treatment based on molecular profiling leads to prolonged survival.

Conclusions:

• Molecularly targeted therapies have transformed the management of advanced NSCLC.
• Early and accurate molecular diagnostics are essential for effective treatment selection.
• The landscape of NSCLC treatment is shifting towards personalized medicine, with TKIs offering significant advantages for patients with specific driver mutations.